Navigation Links
Melanoma Drug Boosts Recurrence-Free Survival
Date:7/11/2008

Pegylated inteferon cut risk 15% but did not reduce overall mortality rates

FRIDAY, July 11 (HealthDay News) -- A chemically modified form of interferon improves the chances that melanoma patients will survive and have no recurrence of the skin cancer, according to a new report.

Dutch researchers, who published their findings in this week's edition of The Lancet, said their study found long-term treatment with pegylated IFNa2b cut the risk of a recurrence by 15 percent over a four-year period.

However, the patients' overall survival rates did not improve, and the treatment was discontinued in 30 percent of the 627 patients because of toxicity. The most common side effects in all patients were liver toxicity, fatigue and depression.

In an accompanying comment in The Lancet, two American doctors concluded that the treatment is still worthwhile, however.

"For the large group of patients with melanoma found in their sentinel node, we believe this regimen will be an attractive alternative to high-dose interferon. Some patients with macroscopic nodal disease who would not tolerate or accept high-dose interferon will also want to consider this approach," wrote Vernon Sondak, of the University of South Florida College of Medicine in Tampa, and Lawrence Flaherty, of the Wayne State University School of Medicine in Michigan.

More information

The National Cancer Institute has more about melanoma.



-- Kevin McKeever



SOURCE: The Lancet, news release, July 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Melanoma Diagnosis Often Delayed for Rural Poor
2. Melanoma drug revs immune cells but cancer cells ignore it
3. Promising drug combination may help those with ocular melanoma that has spread
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. New type of drug shows promise in attacking melanoma in an innovative way
7. Genes Unlock New Treatments for Deadly Melanoma
8. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
9. Researchers Hone in on Cancer Stem Cells for Melanoma
10. Melanomas may appear noticeably different than other moles
11. Melanomas Present Unique Appearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... ... possible to see through objects, has announced the winners of its "Power to ... its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . Creators cast submissions ...
(Date:6/28/2017)... NE (PRWEB) , ... June 28, 2017 , ... ... Medical has been recognized for excellence in employee engagement. Omaha-based C&A ... the Achievers 50 Most Engaged Workplaces™ in North America for 2017. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and ... , No matter on which side of the Atlantic devicemakers do business, this fully ... have to follow. , In addition to the full text of the FDA’s regulations ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest ... minutes, at least one person dies as a direct result from an eating disorder ... for qualified treatment providers. The iaedp Foundation meets this challenge by offering what has ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation ... award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays ... regional supplier of garden pea seed. As demand grew, the small company located in ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: